Pharm Rise Baltic - Company finances
|
EUR
|
2024
From: 2024-02-05
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 2,291 | 6,714 |
| Profit before tax | -14,289 | -5,032 |
| Net profit | -14,289 | -5,032 |
| Equity | -14,288 | -19,318 |
| Liabilities | 17,669 | 26,080 |
| Non-current assets | 0 | 584 |
| Current assets | 3,381 | 6,178 |
| Total assets | 3,381 | 6,762 |
|
Financial indicators
|
||
| Revenue change y/y | - | +193.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -422.6% | -74.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -623.7% | -74.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -623.7% | -74.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharm Rise Baltic - Social security debts
The amount of overdue SODRA debt for the company Pharm Rise Baltic as of the last working day is: 22 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-15 | 21.92 |
| 2026-09-01 | 2026-09-02 | 21.92 |
| 2026-08-01 | 2026-08-09 | 41.44 |
| 2026-07-01 | 2026-07-31 | 60.96 |
| 2026-06-02 | 2026-06-30 | 80.48 |
| 2026-05-06 | 2026-05-24 | 152.34 |
| 2026-05-05 | 2026-05-05 | 313.30 |
| 2026-05-03 | 2026-05-04 | 413.30 |
| 2026-04-20 | 2026-04-30 | 332.82 |
| 2026-04-01 | 2026-04-19 | 574.32 |
| 2026-03-09 | 2026-03-31 | 332.88 |
| 2026-03-03 | 2026-03-08 | 482.88 |
| 2026-02-03 | 2026-03-02 | 241.44 |
| 2026-01-15 | 2026-02-02 | 144.45 |
| 2026-01-01 | 2026-01-14 | 216.15 |
Pharm Rise Baltic - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharm Rise Baltic, MB (code 306676255) is a Small partnership engaged in the manufacture of other food products n.e.c. In the latest financial year 2025, the company generated EUR 6.7K in revenue, up from EUR 2.3K in 2024, indicating a strong increase from a very low base. Despite higher turnover, it remained loss-making, reporting a net loss of EUR 5.0K in 2025 compared with EUR 14.3K in 2024, so the loss narrowed materially as revenue expanded. The 2025 profit margin was negative, reflecting that operating scale was still limited relative to costs. Balance sheet figures remained small: total assets increased to EUR 6.8K from EUR 3.4K a year earlier, while liabilities rose from EUR 17.7K to EUR 26.1K and equity stayed negative at EUR -19.3K. Asset turnover in 2025 was 0.99x, showing revenue broadly matched the asset base. No staff data is provided, so revenue per employee cannot be assessed.